Intraoperative Radiation Therapy (IORT) Market

Intraoperative Radiation Therapy (IORT) Market Analysis and Forecast by Fact.MR

• The global intraoperative radiation therapy (IORT) market is estimated at US$ 131.5 million in 2025 and has been forecast to expand at a CAGR of 8.4% to reach US$ 319.3 million by 2036.
• IORT delivers a concentrated dose of radiation directly to the tumor bed during surgery, immediately following tumor excision, reducing the need for extended post-operative external beam radiation courses.
• The market covers mobile and standalone IORT systems using electron beam and low-energy X-ray technologies, along with treatment planning software.
• Breast cancer treatment, particularly as an adjunct to breast-conserving surgery, is the dominant clinical application. Hospitals and cancer specialty centers form the primary treatment setting.

Summary of Intraoperative Radiation Therapy (IORT) Market

• Market Snapshot
  • In 2025, the global Intraoperative Radiation Therapy (IORT) Market was valued at approximately USD 131.5 million.
  • The market is estimated to reach USD 142.5 million in 2026 and is projected to attain USD 319.3 million by 2036.
  • The intraoperative radiation therapy (iort) market is likely to expand at a CAGR of 8.4% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 176.8 million between 2026 and 2036.
  • Mobile Intraoperative Radiation Therapy Systems accounts for 37.8% of product share in 2026.
  • India (9.6%) and China (9.3%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Breast-conserving surgery volume growth and the clinical desire to minimize post-operative radiation courses are sustaining demand for intraoperative radiation as a single-session boost or replacement for multi-week external beam therapy.
  • Clinical trial evidence, including TARGIT-A and ELIOT trials, supporting IORT efficacy for early-stage breast cancer is improving clinical acceptance and guideline inclusion.
  • Mobile IORT system development by Carl Zeiss Meditec (INTRABEAM) and IntraOp Medical has made IORT accessible to hospitals without dedicated radiation bunkers.
  • Treatment cost reduction through single-fraction radiation delivery that eliminates weeks of daily external beam therapy sessions is creating health economic justification for IORT adoption.
  • Application expansion beyond breast cancer into brain, gastrointestinal, gynecological, and soft tissue tumors is broadening the clinical indication base for IORT systems.
• Product and Segment View
  • Mobile Intraoperative Radiation Therapy Systems accounts for 37.8% of the product segment in 2026, supported by strong installed base and continued procurement across primary end use channels.
  • Electron Beam Intraoperative Radiation Therapy accounts for 34.6% of the technology segment in 2026, reflecting concentrated demand across established application areas.
  • Breast Cancer Treatment accounts for 42.1% of the application segment in 2026, with adoption rising across both developed and emerging markets.
• Key segmentation includes:
  • Product: Mobile Intraoperative Radiation Therapy Systems, Standalone Intraoperative Radiation Therapy Systems, Software and Treatment Planning Systems
  • Technology: Electron Beam Intraoperative Radiation Therapy, Low Energy X Ray Intraoperative Radiation Therapy, Image Guided Intraoperative Radiation Therapy
  • Application: Breast Cancer Treatment, Brain Tumor Treatment, Gastrointestinal Cancer Treatment
  • End Use: Hospitals, Ambulatory Surgical Centers, Specialty Cancer Clinics
• These systems enable:
  • Targeted procurement and specification alignment across buyer segments
  • Performance benchmarking across product and application categories
  • Regional demand mapping across 30 plus countries
  • Geography and Competitive Outlook
  • North America accounts for a large share of global demand, supported by established procurement channels and a mature buyer base.
  • Europe shows stable demand, with Germany (8.1%) contributing through regulatory compliance and institutional procurement for intraoperative radiation therapy (iort) products.
  • Asia Pacific demand is led by India (9.6%) and China (9.3%).
  • India (9.6%) and China (9.3%) are the fastest growing country markets during the forecast period.
  • Leading companies include Carl Zeiss Meditec AG, IntraOp Medical, Inc., Elekta, S.I.T. Sordina IORT Technologies S.p.A., IBA Worldwide.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The IORT market is a specialized radiation oncology category where growth is driven by breast cancer treatment volume, clinical evidence maturation, and equipment portability improvement. Carl Zeiss Meditec leads through INTRABEAM market share and clinical trial data. The market remains small relative to external beam radiation because IORT is appropriate only for selected patients, but within that niche, the clinical and economic value proposition is compelling. Application expansion beyond breast into brain, GI, and gynecological tumors will define the next phase of growth, and image-guided IORT technology is the enabler.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Breast-conserving surgery volume growth and the clinical desire to minimize post-operative radiation courses are sustaining demand for intraoperative radiation as a single-session boost or replacement for multi-week external beam therapy.
• Clinical trial evidence, including TARGIT-A and ELIOT trials, supporting IORT efficacy for early-stage breast cancer is improving clinical acceptance and guideline inclusion.
• Mobile IORT system development by Carl Zeiss Meditec (INTRABEAM) and IntraOp Medical has made IORT accessible to hospitals without dedicated radiation bunkers.

Key Market Constraints

• High equipment acquisition cost for IORT systems, typically exceeding USD 500,000, creates capital budget barriers for smaller cancer centers and community hospitals.
• Surgical workflow disruption from intraoperative radiation delivery adds 20 to 40 minutes to operative time, creating logistical resistance from surgeons and operating room scheduling teams.
• Limited long-term follow-up data beyond 10 years for IORT as sole radiation treatment in early breast cancer creates clinical uncertainty among some radiation oncologists.

Key Opportunity Areas

• Single-fraction definitive IORT as a replacement for multi-week external beam radiation in selected early breast cancer patients represents the highest-value clinical proposition.
• Image-guided IORT integration with intraoperative CT and ultrasound is improving dose targeting precision and expanding treatable tumor locations beyond accessible superficial sites.
• Emerging market cancer treatment infrastructure expansion is creating first-time IORT procurement demand in institutions building comprehensive oncology programs.

Segment-wise Analysis of the Intraoperative Radiation Therapy (IORT) Market

• Mobile Intraoperative Radiation Therapy Systems holds 37.8% of the product segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Electron Beam Intraoperative Radiation Therapy holds 34.6% of the technology segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Breast Cancer Treatment holds 42.1% of the application segment in 2026, supported by established demand channels and continued procurement across primary end use applications.

The intraoperative radiation therapy (iort) market is segmented by product, technology, application, end use, and region.

By product, the market covers Mobile Intraoperative Radiation Therapy Systems, Standalone Intraoperative Radiation Therapy Systems, Software and Treatment Planning Systems.

By technology, coverage includes Electron Beam Intraoperative Radiation Therapy, Low Energy X Ray Intraoperative Radiation Therapy, Image Guided Intraoperative Radiation Therapy.

Which Product Segment Dominates the Intraoperative Radiation Therapy (IORT) Market?

Mobile Intraoperative Radiation Therapy Systems is expected to account for 37.8% of the product segment in 2026. Within this category, Low Energy X Ray Based Systems, Electron Beam Based Systems, Integrated Linear Accelerator Systems represent the primary sub-segments generating procurement activity. The depth of the mobile intraoperative radiation therapy systems installed base across product applications sustains replacement demand and limits share erosion from newer alternatives in the intraoperative radiation therapy (iort) market.

Standalone Intraoperative Radiation Therapy Systems is the second largest category in the product segment, with demand concentrated in Conventional Linear Accelerator Units and Compact Electron Beam Systems. Growth in standalone intraoperative radiation therapy systems reflects shifting buyer requirements within the intraoperative radiation therapy (iort) market toward this category.

Which Technology Segment Dominates the Intraoperative Radiation Therapy (IORT) Market?

Electron Beam Intraoperative Radiation Therapy is expected to account for 34.6% of the technology segment in 2026. Within this category, Low Energy Electron Therapy, High Energy Electron Therapy represent the primary sub-segments generating procurement activity. The depth of the electron beam intraoperative radiation therapy installed base across technology applications sustains replacement demand and limits share erosion from newer alternatives in the intraoperative radiation therapy (iort) market.

Low Energy X Ray Intraoperative Radiation Therapy is the second largest category in the technology segment, with demand concentrated in Surface Treatment X Ray Systems and Penetration Controlled X Ray Systems. Growth in low energy x ray intraoperative radiation therapy reflects shifting buyer requirements within the intraoperative radiation therapy (iort) market toward this category.

Which Application Segment Dominates the Intraoperative Radiation Therapy (IORT) Market?

Breast Cancer Treatment is expected to account for 42.1% of the application segment in 2026. Within this category, Breast Conserving Surgery Adjunct Therapy, Recurrence Prevention Therapy represent the primary sub-segments generating procurement activity. The depth of the breast cancer treatment installed base across application applications sustains replacement demand and limits share erosion from newer alternatives in the intraoperative radiation therapy (iort) market.

Brain Tumor Treatment is the second largest category in the application segment, with demand concentrated in Glioma Treatment Support and Metastatic Brain Lesion Management. Growth in brain tumor treatment reflects shifting buyer requirements within the intraoperative radiation therapy (iort) market toward this category.

Which Product Trend is Shaping the Next Phase of Growth in the Intraoperative Radiation Therapy (IORT) Market?

Mobile low-energy X-ray IORT systems are the technology category driving market accessibility expansion. Carl Zeiss Meditec INTRABEAM system delivers targeted kilovoltage X-rays through a miniature source placed directly in the tumor bed, requiring no dedicated shielding vault and fitting within standard operating rooms. This portability removes the infrastructure barrier that previously limited IORT to large cancer centers with specialized radiation facilities.

The clinical and economic case for mobile IORT is strongest in early-stage breast cancer where a single intraoperative radiation treatment can replace 3 to 6 weeks of daily external beam therapy. For patients, the reduction in treatment burden improves quality of life and compliance. For health systems, the elimination of outpatient radiation visits generates cost savings that can justify the equipment investment. The TARGIT-A randomized controlled trial demonstrated non-inferior outcomes for risk-adapted IORT in selected patients, providing the clinical evidence base that underpins adoption.

Regional Outlook Across Key Markets

• India is growing at 9.6%, supported by cancer infrastructure expansion, clinical adoption at leading centers, and cost-effective treatment rationale.
• China is growing at 9.3%, supported by hospital cancer center expansion, radiation oncology development, and breast cancer incidence growth.
• USA is growing at 8.7%, supported by TARGIT-A trial evidence, academic cancer center programs, and CMS reimbursement coverage.
• Japan is growing at 8.4%, supported by established radiation oncology programs, clinical guideline development, and rising breast cancer incidence.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Intraoperative Radiation Therapy (IORT) in India

The India Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 9.6% through 2036. India is the fastest-growing IORT market, driven by expanding cancer treatment infrastructure and clinical adoption at leading oncology centers.

• Tata Memorial Hospital and Rajiv Gandhi Cancer Institute have established IORT programs using INTRABEAM for breast cancer treatment.
• Cost savings from single-fraction radiation versus multi-week external beam courses create a compelling economic case in the Indian healthcare setting.
• Growing breast cancer diagnosis rates and breast-conserving surgery adoption expand the eligible patient population for IORT.

Intraoperative Radiation Therapy (IORT) Demand Trends in China

The China Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 9.3% through 2036. Hospital cancer center expansion and radiation oncology capability development are supporting IORT adoption in China.

• Tier-1 city comprehensive cancer centers are evaluating and installing IORT systems as part of multi-modality oncology programs.
• Growing breast cancer incidence and breast-conserving surgery rates expand the clinical indication base for intraoperative radiation.
• Government hospital oncology department investment creates capital budget access for high-value radiation equipment procurement.

USA Intraoperative Radiation Therapy (IORT) Market Growth Outlook

The USA Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 8.7% through 2036. The U.S. is a major IORT market, with clinical adoption supported by TARGIT-A trial evidence and breast cancer treatment volume.

• ASTRO clinical guidelines acknowledge IORT as an option for selected early-stage breast cancer patients, supporting clinical adoption.
• Academic medical centers and NCI-designated cancer centers maintain the largest IORT programs and generate clinical evidence.
• CMS reimbursement for IORT (CPT 77424, 77425) provides financial viability for hospital IORT program development.

Japan Intraoperative Radiation Therapy (IORT) Market Demand Analysis

The Japan Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 8.4% through 2036. Established radiation oncology programs and clinical guideline development support IORT adoption in Japan.

• National Cancer Center Japan and university hospital radiation oncology departments maintain IORT capabilities.
• Japanese Society for Radiation Oncology guideline development supports evidence-based IORT adoption for appropriate indications.
• Aging population demographics and rising breast cancer incidence expand the patient population eligible for breast-conserving surgery with IORT.

Intraoperative Radiation Therapy (IORT) Market Growth Assessment in Germany

The Germany Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 8.1% through 2036. Germany is a leading European IORT market, with Carl Zeiss Meditec domestic presence and strong clinical research programs.

• University hospital breast centers in Mannheim, Munich, and Hamburg have established IORT programs with published clinical outcome data.
• Carl Zeiss Meditec, headquartered in Jena, Germany, maintains strong domestic clinical relationships and installation support.
• German Cancer Society (DKG) breast center certification supports standardized clinical pathways that include IORT as a treatment option.

Intraoperative Radiation Therapy (IORT) Market Opportunity Outlook in UK

The UK Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 7.9% through 2036. NHS cancer treatment modernization and clinical trial participation support IORT adoption in the United Kingdom.

• University College London Hospital TARGIT-A trial leadership has positioned the U.K. as a clinical evidence center for IORT.
• NHS England cancer treatment service specifications accommodate IORT delivery within breast cancer treatment pathways.
• NICE technology assessment engagement with IORT evidence supports potential pathway for NHS-wide adoption recommendations.

Demand Landscape for Intraoperative Radiation Therapy (IORT) in Brazil

The Brazil Intraoperative Radiation Therapy (IORT) market is projected to grow at a CAGR of 7.4% through 2036. Growing oncology infrastructure and breast cancer treatment capacity support emerging IORT demand in Brazil.

• Private cancer hospitals in Sao Paulo and Rio de Janeiro are evaluating IORT systems for breast cancer treatment programs.
• Growing breast cancer screening and diagnosis rates expand the population eligible for breast-conserving surgery with IORT.
• SUS cancer treatment protocol development could incorporate IORT for selected indications as clinical evidence matures.

Competitive Benchmarking and Company Positioning

Intraoperative Radiation Therapy (IORT) Market Analysis By Company

• Carl Zeiss Meditec AG, IntraOp Medical, Inc., Elekta, S.I.T. Sordina IORT Technologies S.p.A. hold established positions in the global intraoperative radiation therapy (iort) market through broad product portfolios, geographic reach, and growing capabilities in higher specification categories.
• IBA Worldwide, Eckert & Ziegler, IsoRay, Inc., PTW-Freiburg GmbH participate across specific price tiers, end use segments, and regional channels, with competition shaped by product quality, service support, and distribution access.
• Clinical evidence depth from randomized trials, system portability and operating room compatibility, applicator versatility across tumor sites, and radiation oncologist training program reach are the primary competitive differentiators.

Carl Zeiss Meditec AG leads the IORT market through its INTRABEAM low-energy X-ray system and the largest global installed base. IntraOp Medical Inc. competes with its Mobetron mobile electron beam IORT system. Elekta participates through its broader radiation therapy portfolio. S.I.T. Sordina IORT Technologies serves European markets with specialized electron beam systems. IBA Worldwide participates through its proton and radiation therapy equipment portfolio.

The IORT market is concentrated between two primary system types: low-energy X-ray (Carl Zeiss Meditec) and mobile electron beam (IntraOp Medical), with each technology having distinct clinical advantages. Competition is shaped by clinical trial data, key opinion leader endorsement, and training program availability. The small total market size limits new entrant investment, creating a stable competitive structure dominated by established specialists.

Key Companies in the Intraoperative Radiation Therapy (IORT) Market

• Carl Zeiss Meditec AG, IntraOp Medical, Inc., Elekta, S.I.T. Sordina IORT Technologies S.p.A. are among the leading players in the intraoperative radiation therapy (iort) market globally, supported by strong brand visibility and broad product portfolios.
• IBA Worldwide, Eckert & Ziegler, IsoRay, Inc., PTW-Freiburg GmbH hold established positions across specific categories, supported by durable products and regional distribution.

Recent Industry Developments

• Carl Zeiss Meditec AG - Image-Guided IORT System (January 2026)
  • Carl Zeiss Meditec AG launched an image-guided IORT system integrating intraoperative ultrasound with targeted X-ray delivery, improving dose targeting precision for breast and soft tissue tumor bed irradiation.
• IntraOp Medical, Inc. - Multi-Site Applicator Kit (2025)
  • IntraOp Medical, Inc. introduced an expanded applicator kit enabling IORT delivery across breast, brain, and gastrointestinal tumor locations, broadening the clinical utility of its mobile IORT platform.
• Elekta - Real-Time Dosimetry Module (2025)
  • Elekta released a real-time dosimetry monitoring module for its IORT system that provides live dose verification during treatment delivery, improving quality assurance and treatment accuracy.
• S.I.T. Sordina IORT Technologies S.p.A. - Clinical Outcomes Registry (February 2026)
  • S.I.T. Sordina IORT Technologies S.p.A. announced the establishment of a multi-institutional IORT clinical outcomes registry collecting prospective treatment data across breast and non-breast tumor indications to strengthen the evidence base.

Leading Companies Shaping the Intraoperative Radiation Therapy (IORT) Market

• Carl Zeiss Meditec AG
• IntraOp Medical, Inc.
• Elekta
• S.I.T. Sordina IORT Technologies S.p.A.
• IBA Worldwide
• Eckert & Ziegler
• IsoRay, Inc.
• PTW-Freiburg GmbH
• CIVCO Radiotherapy
• Radcore Systems

Sources and Research References

• Carl Zeiss Meditec AG. Product portfolio and corporate announcements.
• IntraOp Medical, Inc.. Product portfolio and corporate announcements.
• Elekta. Product portfolio and corporate announcements.
• Industry association statistics, regulatory publications, trade databases, and company product catalogs.
• Primary interviews with manufacturers, distributors, buyers, and institutional users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Intraoperative Radiation Therapy (IORT) Market?
• How fast is the Intraoperative Radiation Therapy (IORT) Market expected to grow between 2026 and 2036?
• Which product is likely to lead the market by 2026?
• Which technology segment is expected to account for the highest demand by 2026?
• What factors are driving demand in this market globally?
• How is technology adoption influencing the market structure?
• Which countries are projected to show the fastest growth through 2036?
• What is driving market expansion in India and China?
• Who are the key companies active in the Intraoperative Radiation Therapy (IORT) Market?
• How does Fact.MR estimate and validate the market forecast?

Intraoperative Radiation Therapy (IORT) Market Definition

The intraoperative radiation therapy (iort) market covers products, technologies, and services associated with product, technology, application categories. The scope includes global and regional market size and forecasts for 2026 to 2036 across product, technology, application, end use, and region.

Intraoperative Radiation Therapy (IORT) Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product, technology, application, end use, and region.
• It includes regional demand analysis across major geographies, based on factors such as technology adoption, regulatory requirements, institutional spending, and commercial demand patterns.
• The report includes pricing and cost analysis across entry-level, mid-range, and premium categories, including hardware, software, and service components where applicable.
• It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, pricing strategy, geographic reach, and distribution expansion of leading players.

Intraoperative Radiation Therapy (IORT) Market Exclusions

• The scope excludes adjacent categories, general-purpose alternatives, and products not specifically classified under the intraoperative radiation therapy (iort) market taxonomy.
• It excludes custom-built in-house solutions, informal unbranded products with low market visibility, and rental or leasing services without direct product sales.
• The report excludes military or defense-grade variants, industrial systems outside the defined scope, and non-commercial applications without market transaction data.
• It also excludes software-only platforms sold independently from hardware, unless they are part of the defined product or service taxonomy.

Intraoperative Radiation Therapy (IORT) Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120 plus secondary sources and benchmarks 65 plus company product portfolios.
• Market sizing covers 30 plus countries through a demand-side model, supported by top-down validation.
• Key inputs include end use adoption rates, technology penetration, pricing benchmarks, and regional procurement patterns.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25 plus interviews across manufacturers, distributors, buyers, and institutional users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.